These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 31254002)

  • 1. Targeting very early systemic sclerosis: a case-based review.
    Melissaropoulos K; Kraniotis P; Bogdanos D; Dimitroulas T; Sakkas L; Daoussis D
    Rheumatol Int; 2019 Nov; 39(11):1961-1970. PubMed ID: 31254002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.
    Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C
    Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
    Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
    J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: association with enhanced resolution of skin fibrosis.
    Daoussis D; Tsamandas A; Antonopoulos I; Filippopoulou A; Papachristou DJ; Papachristou NI; Andonopoulos AP; Liossis SN
    Arthritis Res Ther; 2016 May; 18(1):118. PubMed ID: 27208972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center.
    Vilela VS; Maretti GB; Gama LM; Costa CH; Rufino RL; Levy RA
    Rev Bras Reumatol Engl Ed; 2016; 56(5):458-463. PubMed ID: 27692396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis.
    Goswami RP; Ray A; Chatterjee M; Mukherjee A; Sircar G; Ghosh P
    Rheumatology (Oxford); 2021 Feb; 60(2):557-567. PubMed ID: 33164098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. A single-centre case series study.
    Fraticelli P; Fischetti C; Salaffi F; Carotti M; Mattioli M; Pomponio G; Gabrielli A
    Clin Exp Rheumatol; 2018; 36 Suppl 113(4):142-145. PubMed ID: 30277864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of rituximab for the treatment of refractory systemic sclerosis associated calcinosis: A case series and systematic review of the literature.
    Narváez J; Pirola JP; LLuch J; Juarez P; Nolla JM; Valenzuela A
    Autoimmun Rev; 2019 Mar; 18(3):262-269. PubMed ID: 30639647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of rituximab on disease activity, severity, and disease-related damage in patients with immunosuppressive-resistant systemic sclerosis.
    Yalçinkaya Y; Artim Esen B; Amikishiyev S; Aliyeva N; Gül A; Öcal L; Inanç M
    Turk J Med Sci; 2023; 53(6):1704-1712. PubMed ID: 38813512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease.
    Daoussis D; Melissaropoulos K; Sakellaropoulos G; Antonopoulos I; Markatseli TE; Simopoulou T; Georgiou P; Andonopoulos AP; Drosos AA; Sakkas L; Liossis SN
    Semin Arthritis Rheum; 2017 Apr; 46(5):625-631. PubMed ID: 27839742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
    Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
    Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful long-term systemic sclerosis treatment by high-frequent low-dose B cell-depleting therapy.
    Moazedi-Fuerst FC; Lackner A; Kreuzer SM; Eller K; Odler B; Kovacs G; Flick H; Talakic E; Hermann J; Venhoff N; Venhoff A; Hafner F; Brodmann M; Jud P; Yazdani-Biuki B; Husic R; Salmhofer W; Stradner MH; Graninger WB; Thiel J; Brezinschek HP
    J Autoimmun; 2024 Jul; 147():103246. PubMed ID: 38788540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study.
    Elhai M; Boubaya M; Distler O; Smith V; Matucci-Cerinic M; Alegre Sancho JJ; Truchetet ME; Braun-Moscovici Y; Iannone F; Novikov PI; Lescoat A; Siegert E; Castellví I; Airó P; Vettori S; De Langhe E; Hachulla E; Erler A; Ananieva L; Krusche M; López-Longo FJ; Distler JHW; Hunzelmann N; Hoffmann-Vold AM; Riccieri V; Hsu VM; Pozzi MR; Ancuta C; Rosato E; Mihai C; Kuwana M; Saketkoo LA; Chizzolini C; Hesselstrand R; Ullman S; Yavuz S; Rednic S; Caimmi C; Bloch-Queyrat C; Allanore Y;
    Ann Rheum Dis; 2019 Jul; 78(7):979-987. PubMed ID: 30967395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is rituximab effective for systemic sclerosis? A systematic review and meta-analysis.
    de Figueiredo Caldas MMV; de Azevedo KPM; de França Nunes AC; de Oliveira VH; Pimenta IDSF; de Araújo IDT; Neto FAB; da Silveira Gonçalves de Oliveira AK; Piuvezam G
    Adv Rheumatol; 2021 Feb; 61(1):15. PubMed ID: 33640020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis.
    Daoussis D; Liossis SN; Tsamandas AC; Kalogeropoulou C; Paliogianni F; Sirinian C; Yiannopoulos G; Andonopoulos AP
    Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S17-22. PubMed ID: 22244622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of rituximab on lung and skin involvement in systemic sclerosis: a systematic review and metaanalysis.
    Borrirukwisitsak S; Tantayakom P; Katchamart W
    Clin Rheumatol; 2021 Jul; 40(7):2779-2789. PubMed ID: 33428098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab on lung, skin, and joint involvement in patients with systemic sclerosis: A case series study and review of the literature.
    Yarkan Tuğsal H; Zengin B; Kenar G; Önen F; Birlik M
    Int J Rheum Dis; 2022 Jul; 25(7):755-768. PubMed ID: 35535670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in biological and targeted therapies for systemic sclerosis.
    Mulcaire-Jones E; Low AHL; Domsic R; Whitfield ML; Khanna D
    Expert Opin Biol Ther; 2023 Apr; 23(4):325-339. PubMed ID: 36964674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab for rapidly progressive juvenile systemic sclerosis.
    Zulian F; Dal Pozzolo R; Meneghel A; Castaldi B; Marcolongo R; Caforio ALP; Martini G
    Rheumatology (Oxford); 2020 Dec; 59(12):3793-3797. PubMed ID: 32442284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of rituximab therapy in patients with systemic sclerosis disease (SSc): systematic review and meta-analysis.
    Moradzadeh M; Aghaei M; Mehrbakhsh Z; Arab-Bafrani Z; Abdollahi N
    Clin Rheumatol; 2021 Oct; 40(10):3897-3918. PubMed ID: 33796953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.